Latest News and Press Releases

Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.

Longeveron to present at the Roth investor conference taking place March 17-18, 2025. Company fireside chat Tuesday, March 18th at 9:00am PT.

Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment.

WHO approved generic name laromestrocel for stem cell therapy Lomecel-B, being developed as potential treatment for Alzheimer's disease and HLHS.

Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.

Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.

Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).

Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.

Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th